BridgeBio Pharma, Inc.

Report initial clinical data for BBP-631 AAV5 gene therapy candidate

Deadline passed; outcome being checked

Announced: 26 Feb 2021
Due: 31 Mar 2022
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“with initial data anticipated in late 2021 or early 2022”

SourceBridgeBio Pharma, Inc. Form 8-K press release, 2021-02-26
FilingSEC filing index
Deadline as statedlate 2021 or early 2022
Deadline used31 Mar 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-BBIO-024753
Cite as https://keptindex.org/c/KI-C-2021-BBIO-024753/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Initial clinical data for BBP-631 gene therapy
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you BridgeBio Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-BBIO-024753 · Corrections policy